Clinical trials: Fulminant Clostridium Difficile Colitis
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Clostridium Difficile Colitis
Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis
The investigators hypothesize that minimally invasive ileal diversion with intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution will clear Clostridium difficile infection resulting in…
- Trial name
- NCT01441271
- Testing
- Ileal diversion and lavage, total abdominal colectomy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Fulminant Clostridium Difficile Colitis
Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis
LAY SUMMARY Clostridium Difficile (C.difficile) is a bacterial infection that can cause an inflammation of the colon, (C.difficile colitis). This sometimes progresses to a sudden and severe illness.
- Trial name
- NCT02347280
- Testing
- Loop Ileostomy with colonic lavage, Total Abdominal Colectomy with end ileostomy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Jewish General Hospital